AZD-3463ALK/IGF1R inhibitor CAS# 1356962-20-3 |
- ASP3026
Catalog No.:BCC1372
CAS No.:1097917-15-1
- AP26113
Catalog No.:BCC1069
CAS No.:1197958-12-5
- ALK inhibitor 1
Catalog No.:BCC1339
CAS No.:761436-81-1
- ALK inhibitor 2
Catalog No.:BCC1340
CAS No.:761438-38-4
- (R)-Crizotinib
Catalog No.:BCC1284
CAS No.:877399-52-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1356962-20-3 | SDF | Download SDF |
PubChem ID | 56599293 | Appearance | Powder |
Formula | C24H25ClN6O | M.Wt | 448.95 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | ALK/IGF1R inhibitor | ||
Solubility | DMSO : 20 mg/mL (44.55 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | N-[4-(4-aminopiperidin-1-yl)-2-methoxyphenyl]-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine | ||
SMILES | COC1=C(C=CC(=C1)N2CCC(CC2)N)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl | ||
Standard InChIKey | GCYIGMXOIWJGBU-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C24H25ClN6O/c1-32-22-12-16(31-10-8-15(26)9-11-31)6-7-21(22)29-24-28-14-19(25)23(30-24)18-13-27-20-5-3-2-4-17(18)20/h2-7,12-15,27H,8-11,26H2,1H3,(H,28,29,30) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | AZD3463 is a novel orally bioavailable inhibitor of ALK with a Ki value of 0.75 nM. | |||||
Targets | ALK | |||||
IC50 | 0.75 nM(Ki) |
AZD-3463 Dilution Calculator
AZD-3463 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2274 mL | 11.1371 mL | 22.2742 mL | 44.5484 mL | 55.6855 mL |
5 mM | 0.4455 mL | 2.2274 mL | 4.4548 mL | 8.9097 mL | 11.1371 mL |
10 mM | 0.2227 mL | 1.1137 mL | 2.2274 mL | 4.4548 mL | 5.5685 mL |
50 mM | 0.0445 mL | 0.2227 mL | 0.4455 mL | 0.891 mL | 1.1137 mL |
100 mM | 0.0223 mL | 0.1114 mL | 0.2227 mL | 0.4455 mL | 0.5569 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Target: ALK, IGF1R
IC50: 0.75 nM(Ki)
AZD3463 is a novel orally bioavailable ALK/IGF1R inhibitor with Ki value of 0.75 nM. ALK expression is largely restricted to neurons and upregulated in neuroblastoma. Activated ALK has been shown to promote cell survival and growth. High ALK expression or mutations in the ALK gene correlates with adverse outcomes in neuroblastoma. Therefore, ALK receptor tyrosine kinase is an important therapeutic target for drug development against neuroblastoma [1].
In vitro: AZD3463 (5, 10, 20, and 50 μM) effectively inhibited the proliferation of neuroblastoma cell lines with wild type ALK (WT) and ALK activating mutations (F1174L and D1091N) via targeting the ALK-mediated PI3K/AKT/mTOR pathway and ultimately induced apoptosis and autophagy in vitro. Moreover, AZD3463 (1 μM) significantly enhanced the cytotoxic effects of doxorubicin (1 μM) on neuroblastoma cells [1]. AZD3463 simultaneously inhibited STAT3 and AKT to augment the cytotoxic effects of temozolomide and further reduce cell growth [2].
In vivo: AZD3463 (15 mg/kg, i.p. injection) showed significant therapeutic efficacy on the growth of the neuroblastoma tumors with WT and F1174L oncogenic mutant ALK in orthotopic xenograft mouse models [1].
References:
1. Wang Y, Wang L, Guan S, Cao W, Wang H, Chen Z, et al. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Sci Rep. 2016;6:19423.
2. Sampson VB, Vetter NS, Kamara DF, Collier AB, Gresh RC, Kolb EA. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways. PLoS One. 2015;10(11):e0142704.
- ent-3-Oxokaurane-16,17-diol
Catalog No.:BCN6188
CAS No.:135683-73-7
- Narchinol B
Catalog No.:BCN7796
CAS No.:1356822-09-7
- Fmoc-Cha-OH
Catalog No.:BCC3160
CAS No.:135673-97-1
- 17-Methylparsonsianidine
Catalog No.:BCN2093
CAS No.:135637-68-2
- CP 80633
Catalog No.:BCC7463
CAS No.:135637-46-6
- Coccineone B
Catalog No.:BCN6464
CAS No.:135626-13-0
- Fmoc-D-His(Trt)-OH
Catalog No.:BCC3504
CAS No.:135610-90-1
- Parsonsianidine
Catalog No.:BCN2109
CAS No.:135601-81-9
- Pneumocandin B0
Catalog No.:BCC5436
CAS No.:135575-42-7
- Nav1.7 inhibitor
Catalog No.:BCC4191
CAS No.:1355631-24-1
- Schisanlignone A
Catalog No.:BCN3628
CAS No.:135557-67-4
- Cudraxanthone L
Catalog No.:BCN6187
CAS No.:135541-40-1
- HG-14-10-04
Catalog No.:BCC5392
CAS No.:1356962-34-9
- N-Acetylglycyl-D-glutamic acid
Catalog No.:BCC6634
CAS No.:135701-69-8
- c-Met inhibitor 1
Catalog No.:BCC1488
CAS No.:1357072-61-7
- ML 228
Catalog No.:BCC2435
CAS No.:1357171-62-0
- MDL 29,913
Catalog No.:BCC5729
CAS No.:135721-56-1
- Palonosetron
Catalog No.:BCC1834
CAS No.:135729-61-2
- Palonosetron hydrochloride
Catalog No.:BCN2171
CAS No.:135729-62-3
- Taxinine M
Catalog No.:BCN6942
CAS No.:135730-55-1
- OG-L002
Catalog No.:BCC4549
CAS No.:1357302-64-7
- Nonin A
Catalog No.:BCN7149
CAS No.:1357351-29-1
- RGFP966
Catalog No.:BCC3991
CAS No.:1357389-11-7
- Boc-Glu(OBzl)-OH
Catalog No.:BCC3389
CAS No.:13574-13-5